Background: Biopsy is the usual gold standard for liver steatosis assessment. The aim of this study was to identify a panel of biomarkers (SteatoTest), with sufficient predictive values ...

Objective Hepatic steatosis accompanying obesity is a major health concern, since it may initiate non-alcoholic fatty liver disease (NAFLD) and associated complications like cirrhosis or cancer.

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...

More than 36 million Americans have type 2 diabetes, a condition primarily attributed to the body's cells not responding to ...

The ORs of MAFLD in the moderate health factors group were 0.67 (95% CI 0.55–0.83 ... The primary limitation of our study lies in utilizing non-invasive USFLI and NFS scores as diagnostic criteria for ...

Nonalcoholic fatty liver disease (NAFLD) includes a series of hepatic manifestations, starting with liver steatosis and potentially evolving towards nonalcoholic steatohepatitis (NASH), fibrosis, ...

Researchers found that high fructose intake, especially from processed foods, is linked to metabolic dysfunction-associated ...

Nonalcoholic fatty liver disease (NAFLD ... It remains unclear why some obese patients with NAFLD have only steatosis whereas others exhibit steatohepatitis, and alcohol consumption could have ...

Assessment of liver fibrosis and cirrhosis is crucial for the management of patients with chronic hepatitis B. The presence of at least moderate liver fibrosis is an important indication for antiviral ...

No dose adjustment is recommended for patients with mild hepatic impairment. The use of Rezdiffra should be avoided in patients with decompensated cirrhosis (consistent with moderate or severe ...

leading to de novo lipogenesis in the liver. 7,8 Why some patients progress from simple steatosis to MASH with inflammation and increased fibrogenesis is complex and not fully understood. Changes in ...